| Year |
Title |
Altmetric |
| 2022
|
Dose Optimization for Single-Channel Vaginal Cylinder High-Dose-Rate Brachytherapy: A Double Prescription Method for Patients With Endometrial Adenocarcinoma..
Cureus.
14:e26303.
2022
|
|
| 2021
|
Selection of brachytherapy applicators based on tumor size and shape for cervical cancer: simulation analysis of pear-shaped isodose dimensions.
Medical Dosimetry.
46:431-434.
2021
|
|
| 2021
|
Molecular imaging of prostate cancer targeting CD46 using immunoPET.
Clinical Cancer Research.
27:1305-1315.
2021
|
|
| 2020
|
Reduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancers..
Cureus.
12:e8618.
2020
|
|
| 2019
|
Electromagnetic Transponder Based Tracking and Gating in the Radiotherapeutic Treatment of Thoracic Malignancies.
Practical Radiation Oncology.
9:456-464.
2019
|
|
| 2019
|
Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis
2019
|
|
| 2019
|
Stereotactic radiosurgery with MLC-defined arcs: Verification of dosimetry, spatial accuracy, and end-to-end tests.
Journal of Applied Clinical Medical Physics.
20:84-98.
2019
|
|
| 2018
|
Dynamics of the vaginal wall dose in HDR interstitial brachytherapy for gynecological cancer: Systematic analysis of phantom vs patient case.
Medical Dosimetry.
43:237-242.
2018
|
|
| 2016
|
A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgery.
Journal of Applied Clinical Medical Physics.
17:246-253.
2016
|
|
| 2016
|
A novel phantom and procedure providing submillimeter accuracy in daily QA tests of accelerators used for stereotactic radiosurgery.
Journal of Applied Clinical Medical Physics.
17:246-253.
2016
|
|
| 2014
|
End-to-end test of spatial accuracy in Gamma Knife treatments for trigeminal neuralgia.
Medical Physics.
41.
2014
|
|
| 2014
|
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
Journal of Nuclear Medicine.
55:1636-1642.
2014
|
|
| 2014
|
Image-guided brachytherapy for cervical cancer: Analysis of D2 cc hot spot in three-dimensional and anatomic factors affecting D2 cc hot spot inorgans at risk.
Brachytherapy.
13:203-209.
2014
|
|
| 2014
|
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
Cancer Biotherapy and Radiopharmaceuticals.
29:12-17.
2014
|
|
| 2014
|
A technique using 99mTc-mebrofenin SPECT for radiotherapy treatment planning for liver cancers or metastases.
Medical Dosimetry.
39:7-11.
2014
|
|
| 2013
|
Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphoma.
Cancer Biotherapy and Radiopharmaceuticals.
28:370-379.
2013
|
|
| 2013
|
Intraoperative ultrasound guidance during intracavitary brachytherapy applicator placement in cervical cancer; The university of alabama at birmingham experience.
International Journal of Gynecological Cancer.
23:559-566.
2013
|
|
| 2012
|
Image-based 3D treatment planning for vaginal cylinder brachytherapy: Dosimetric effects of bladder filling on organs at risk
2012
|
|
| 2012
|
SU‐E‐T‐434: Use of Deformable Registration for Cumulated Dose Calculation in Image‐Guided Intracavitary Bracytherapy for Cervical Cancer.
Medical Physics.
39:3804.
2012
|
|
| 2011
|
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
Cancer Biotherapy and Radiopharmaceuticals.
26:127-133.
2011
|
|
| 2010
|
The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: A case series.
Endoscopy.
42:423-425.
2010
|
|
| 2010
|
Effects of Bladder Distension on Organs at Risk in 3D Image-Based Planning of Intracavitary Brachytherapy for Cervical Cancer
2010
|
|
| 2010
|
Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Journal of Nuclear Medicine.
51:150-157.
2010
|
|
| 2009
|
Development of an accelerated GVF semi-automatic contouring algorithm for radiotherapy treatment planning.
Computers in Biology and Medicine.
39:650-656.
2009
|
|
| 2009
|
Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source..
Journal of Applied Clinical Medical Physics.
10:2903.
2009
|
|
| 2009
|
Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma..
Journal of Clinical Oncology.
27:e13006.
2009
|
|
| 2009
|
MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for 111In-And 90Y-ibritumomab Tiuxetan.
Journal of Nuclear Medicine.
50:644-652.
2009
|
|
| 2009
|
Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source.
Journal of Applied Clinical Medical Physics.
10:90-102.
2009
|
|
| 2009
|
Performance of a commercial macro Monte Carlo dose calculation algorithm for determining output factors of clinical electron fields.
Technology in Cancer Research and Treatment.
8:307-314.
2009
|
|
| 2008
|
Conventional High-Dose-Rate Brachytherapy With Concomitant Complementary IMRT Boost: A Novel Approach for Improving Cervical Tumor Dose Coverage
2008
|
|
| 2008
|
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.
Journal of Nuclear Medicine.
49:279-284.
2008
|
|
| 2007
|
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
2007
|
|
| 2007
|
Image-based three-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: Dose-volume histograms of the bladder, rectum, sigmoid colon, and small bowel.
Brachytherapy.
6:187-194.
2007
|
|
| 2007
|
Intensity modulation with respiratory gating for radiotherapy of the pleural space.
Medical Dosimetry.
32:16-22.
2007
|
|
| 2007
|
SU‐FF‐J‐78: 3‐D Target Localization at the End of Expiration Prior to Respiration‐Gated Radiotherapy Treatment.
Medical Physics.
34:2386.
2007
|
|
| 2007
|
SU‐FF‐T‐372: Registration of Frameless High‐Field MRI to Low‐Field Frame‐Based MRI Images in Leksell Gamma‐Knife (LGK) Radiosurgery.
Medical Physics.
34:2487.
2007
|
|
| 2007
|
TH‐C‐AUD‐03: Impact of Respiratory Motion On Helical Tomotherapy Dose Delivery: A Phantom Study with 3‐D Volumetric Dose Measurements.
Medical Physics.
34:2626-2627.
2007
|
|
| 2006
|
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer
2006
|
|
| 2006
|
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
Clinical Lymphoma, Myeloma and Leukemia.
7:236-238.
2006
|
|
| 2006
|
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Journal of Clinical Oncology.
24:3644-3650.
2006
|
|
| 2006
|
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Journal of Nuclear Medicine.
47:534-542.
2006
|
|
| 2006
|
Comprehensive evaluation of a commercial macro Monte Carlo electron dose calculation implementation using a standard verification data set.
Medical Physics.
33:1540-1551.
2006
|
|
| 2006
|
Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: A volumetric dose measurement study.
Medical Physics.
33:1380-1387.
2006
|
|
| 2005
|
Imaging glioma extent with 131I-TM-601.
Journal of Nuclear Medicine.
46:580-586.
2005
|
|
| 2005
|
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Journal of Nuclear Medicine.
46:642-651.
2005
|
|
| 2005
|
Determination of field size-dependent wedge factors from a few selected measurements.
Journal of Applied Clinical Medical Physics.
6:51-60.
2005
|
|
| 2005
|
Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)).
Cancer Biotherapy and Radiopharmaceuticals.
20:671.
2005
|
|
| 2005
|
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
Journal of Nuclear Medicine.
46:1034-1041.
2005
|
|
| 2005
|
Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
Cancer Biotherapy and Radiopharmaceuticals.
20:662-670.
2005
|
|
| 2005
|
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Cancer Biotherapy and Radiopharmaceuticals.
20:502-513.
2005
|
|
| 2005
|
Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration.
Cancer Biotherapy and Radiopharmaceuticals.
20:467-478.
2005
|
|
| 2005
|
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Cancer Biotherapy and Radiopharmaceuticals.
20:379-390.
2005
|
|
| 2005
|
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Clinical Cancer Research.
11:5920-5927.
2005
|
|
| 2005
|
Clinically useful marrow dosimetry for targeted radionuclide therapy.
Cancer Biotherapy and Radiopharmaceuticals.
20:119-122.
2005
|
|
| 2005
|
Testicular uptake and radiation dose in patients receiving Zevalin™ and Pretarget™ CC49Fusion protein.
Cancer Biotherapy and Radiopharmaceuticals.
20:110-118.
2005
|
|
| 2005
|
Determination of field size-dependent wedge factors from a few selected measurements..
Journal of Applied Clinical Medical Physics.
6:51-60.
2005
|
|
| 2005
|
MO‐D‐I‐609‐07: Combined Scatter Subtraction and Digital Restoration of Ho‐166 Images for Quantification.
Medical Physics.
32:2054.
2005
|
|
| 2005
|
Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.
Journal of Neuro-Oncology.
71:113-119.
2005
|
|
| 2005
|
SU‐EE‐A1‐04: Integrated Complementary IMRT Combined with Image‐Guided HDR Brachytherapy for Cancers of the Uterine Cervix.
Medical Physics.
32:1902.
2005
|
|
| 2005
|
SU‐FF‐J‐123: Residual Tumor Motion in Respiratory Gated CT Treatment Planing.
Medical Physics.
32:1948.
2005
|
|
| 2004
|
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
Clinical Cancer Research.
10:7555-7565.
2004
|
|
| 2004
|
A dynamic supraclavicular field-matching technique for head-and-neck cancer patients treated with IMRT
2004
|
|
| 2004
|
Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer
2004
|
|
| 2004
|
Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer.
Drug Design Reviews Online.
1:333-339.
2004
|
|
| 2004
|
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Blood.
104:227-236.
2004
|
|
| 2004
|
Attenuation of intracavitary applicators in 192Ir-HDR brachytherapy.
Medical Physics.
31:2097-2106.
2004
|
|
| 2003
|
Custom step wedge blocking using dynamic multileaf collimation for parametrial pelvic boost irradiation following brachytherapy for carcinoma of the cervix.
Medical Physics.
30:2699-2702.
2003
|
|
| 2003
|
Dosimetric effect of respiration-gated beam on IMRT delivery.
Medical Physics.
30:2241-2252.
2003
|
|
| 2003
|
A Novel Monoclonal Antibody Design for Radioimmunotherapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:751-759.
2003
|
|
| 2003
|
Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:393-404.
2003
|
|
| 2003
|
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:209-215.
2003
|
|
| 2003
|
Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
Cancer Biotherapy and Radiopharmaceuticals.
18:231-237.
2003
|
|
| 2003
|
Validation of target volume and position in respiratory gated CT planning and treatment.
Medical Physics.
30:3196-3205.
2003
|
|
| 2002
|
Assaying 192Ir line sources using a standard length well chamber.
Medical Physics.
29:2692-2697.
2002
|
|
| 2002
|
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy.
Journal of Nuclear Medicine.
43:1245-1253.
2002
|
|
| 2002
|
Model prediction of treatment planning for dose-fractionated radioimmunotherapy..
Cancer.
94:1264-1269.
2002
|
|
| 2002
|
A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical Cancer Research.
8:2806-2811.
2002
|
|
| 2002
|
Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation.
2002
|
|
| 2001
|
Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
Journal of Nuclear Medicine.
42:1324-1333.
2001
|
|
| 2001
|
Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancer.
Clinical Cancer Research.
7:1561-1568.
2001
|
|
| 2000
|
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
2000
|
|
| 2000
|
Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
Journal of Nuclear Medicine.
41:952-958.
2000
|
|
| 2000
|
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
2000
|
|
| 2000
|
Are Radiometal-Labeled Antibodies Better Than Iodine-131-Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67-, Iodine-131-, and Yttrium-90-Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma.
Clinical Lymphoma, Myeloma and Leukemia.
1:118-126.
2000
|
|
| 1999
|
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma.
Journal of Nuclear Medicine.
40:2014-2020.
1999
|
|
| 1999
|
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
Journal of Nuclear Medicine.
40:2102-2106.
1999
|
|
| 1999
|
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma..
Clinical Cancer Research.
5:3330s-3336s.
1999
|
|
| 1999
|
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A..
Clinical Cancer Research.
5:3243s-3248s.
1999
|
|
| 1999
|
Strategies for developing effective radioimmunotherapy for solid tumors..
Clinical Cancer Research.
5:3219s-3223s.
1999
|
|
| 1999
|
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.
Nuclear Medicine and Biology.
26:841-845.
1999
|
|
| 1999
|
Factors affecting 131I-Lym-1 pharmacokinetics and radiationdosimetry in patients with non-Hodgkin's lymphoma and chroniclymphocytic leukemia.
Journal of Nuclear Medicine.
40:1317-1326.
1999
|
|
| 1999
|
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma..
Clinical Cancer Research.
5:533-541.
1999
|
|
| 1999
|
67Cu- versus 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
Clinical Cancer Research.
5:533-541.
1999
|
|
| 1999
|
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma..
Journal of Nuclear Medicine.
40:302-310.
1999
|
|
| 1999
|
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
Journal of Nuclear Medicine.
40:302-310.
1999
|
|
| 1999
|
Dosimetry for radioimmunotherapy: A rapidly evolving field - Editorial.
Cancer Biotherapy and Radiopharmaceuticals.
14:67-70.
1999
|
|
| 1999
|
Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
Cancer Biotherapy and Radiopharmaceuticals.
14:167-176.
1999
|
|
| 1999
|
Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
Cancer Biotherapy and Radiopharmaceuticals.
14:363-369.
1999
|
|
| 1998
|
Synergistic therapy of breast cancer with Y90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocol
1998
|
|
| 1998
|
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
Clinical Cancer Research.
4:2483-2490.
1998
|
|
| 1998
|
A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.
Journal of Nuclear Medicine.
39:1223-1229.
1998
|
|
| 1998
|
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study
1998
|
|
| 1998
|
Quantification of iodine-131 in tumors using a threshold based on image contrast.
European Journal of Nuclear Medicine and Molecular Imaging.
25:497-502.
1998
|
|
| 1998
|
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
Journal of Nuclear Medicine.
39:842-849.
1998
|
|
| 1998
|
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody.
Cancer Biotherapy and Radiopharmaceuticals.
13:239-254.
1998
|
|
| 1998
|
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
1998
|
|
| 1998
|
Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
Journal of Clinical Oncology.
16:3246-3256.
1998
|
|
| 1998
|
Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
Cancer Biotherapy and Radiopharmaceuticals.
13:1-12.
1998
|
|
| 1997
|
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2..
Cancer.
80:2576-2582.
1997
|
|
| 1997
|
Imaging for improved prediction of myelotoxicity after radioimmunotherapy..
Cancer.
80:2558-2566.
1997
|
|
| 1997
|
Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies..
Cancer.
80:2553-2557.
1997
|
|
| 1997
|
Radioimmunotherapy for breast cancer using indium-11 l/yttrium-90 BrE-3: Results of a phase i clinical trial.
Journal of Nuclear Medicine.
38:1180-1185.
1997
|
|
| 1997
|
Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.
Journal of Nuclear Medicine.
38:1374-1378.
1997
|
|
| 1997
|
Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.
Clinical Cancer Research.
3:1253-1260.
1997
|
|
| 1997
|
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
1997
|
|
| 1997
|
Practical determination of organ S values for individual patients for therapy..
Nuclear Medicine and Biology.
24:447-449.
1997
|
|
| 1997
|
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
Clinical Cancer Research.
3:71-79.
1997
|
|
| 1997
|
Practical determination of organ S values for individual patients for therapy.
Nuclear Medicine and Biology.
24:447-449.
1997
|
|
| 1997
|
Reproducibility of operator processing for radiation dosimetry.
Nuclear Medicine and Biology.
24:77-83.
1997
|
|
| 1997
|
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
1997
|
|
| 1996
|
Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
Journal of Nuclear Medicine.
37:1970-1975.
1996
|
|
| 1996
|
Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy..
European Journal of Nuclear Medicine and Molecular Imaging.
23:953-957.
1996
|
|
| 1996
|
Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator.
Journal of Nuclear Medicine.
37:302-306.
1996
|
|
| 1996
|
A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy.
Nuclear Medicine and Biology.
23:525-532.
1996
|
|
| 1996
|
Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.
Journal of Nuclear Medicine.
37:146-150.
1996
|
|
| 1995
|
Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.
Cancer Research.
55.
1995
|
|
| 1995
|
Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies..
Cancer Research.
55:5893s-5898s.
1995
|
|
| 1995
|
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
Cancer Research.
55.
1995
|
|
| 1995
|
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression..
Cancer Research.
55:5837s-5841s.
1995
|
|
| 1995
|
Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
Clinical Nuclear Medicine.
20:117-125.
1995
|
|
| 1994
|
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3)..
Cancer.
73:1012-1022.
1994
|
|
| 1994
|
Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model..
Cancer.
73:1038-1048.
1994
|
|
| 1994
|
Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3).
Cancer.
73:1012-1022.
1994
|
|
| 1994
|
Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a model.
Cancer.
73:1038-1048.
1994
|
|
| 1994
|
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.
Journal of Nuclear Medicine.
35:1381-1389.
1994
|
|
| 1994
|
Quantitative bremsstrahlung imaging of yttrium-90 using a wiener.
Medical Physics.
21:1409-1417.
1994
|
|
| 1990
|
Photon correlation spectroscopy of the polarization signal from single muscle fibres.
Journal of Muscle Research and Cell Motility.
11:137-146.
1990
|
|
| 1989
|
Polarization states of diffracted light. Changes accompanying fiber activation.
Biophysical Journal.
56:595-605.
1989
|
|
